Matthew Shawn Morris - Apr 11, 2023 Form 4 Insider Report for Privia Health Group, Inc. (PRVA)

Role
Chief Executive Officer, Director
Signature
/s/ Thomas Bartrum, as attorney-in-fact
Stock symbol
PRVA
Transactions as of
Apr 11, 2023
Transactions value $
-$680,292
Form type
4
Date filed
4/13/2023, 04:28 PM
Previous filing
Apr 5, 2023
Next filing
May 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRVA Common Stock, $0.01 par value per share Options Exercise $50.1K +25.1K +20.58% $2.00 147K Apr 11, 2023 Direct
transaction PRVA Common Stock, $0.01 par value per share Sale -$704K -25.1K -17.07% $28.11 122K Apr 11, 2023 Direct F1, F2
transaction PRVA Common Stock, $0.01 par value per share Options Exercise $2K +1K +0.82% $2.00 123K Apr 12, 2023 Direct
transaction PRVA Common Stock, $0.01 par value per share Sale -$28.1K -1K -0.81% $28.08 122K Apr 12, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRVA Stock Option (Right to Purchase) Options Exercise $0 -25.1K -0.57% $0.00 4.4M Apr 11, 2023 Common Stock 25.1K $2.00 Direct F4
transaction PRVA Stock Option (Right to Purchase) Options Exercise $0 -1K -0.02% $0.00 4.4M Apr 12, 2023 Common Stock 1K $2.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.45 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.28 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 All stock options are fully vested and exercisable.